BJMO - , issue ,
L. Albiges
The introduction of immune checkpoint inhibitors dramatically changed the treatment paradigm of patients with advanced RCC. In her lecture, Dr. Laurence Albiges gave an overview of real-life data with nivolumab and gave her insights on how the first-line treatment landscape of patients with advanced RCC will evolve in the years to come.
Read moreBJMO - volume 12, issue 10, march 2018
L. Albiges
The introduction of immune checkpoint inhibitors dramatically changed the treatment paradigm of patients with advanced RCC. In her lecture, Dr. Laurence Albiges gave an overview of real-life data with nivolumab and gave her insights on how the first-line treatment landscape of patients with advanced RCC will evolve in the years to come.
Read moreTo provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.